Chemo plus immunotherapy before and after surgery for bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (pembrolizumab) given before and after surgery for people with bile duct or gallbladder cancer that can be removed. The goal is to see if this approach helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a bile duct or gallbladder cancer that can be surgically removed.
- You are 18 years or older.
- You are in generally good health (able to do daily activities without significant assistance).
- You have not had prior chemotherapy or immunotherapy for this cancer.
- You do not have active autoimmune disease or an organ transplant.
- Women who can become children and men with partners who can become pregnant must agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug given before surgery for bile duct cancer. The goal is to see if this approach shrinks tumors and lowers the chance of cancer coming back after surgery.
This trial tests a combination of drugs given before surgery to shrink bile duct cancer and possibly improve outcomes. The drugs include an immunotherapy (tislelizumab) and three chemotherapy agents (gemcitabine, cisplatin, and S-1).
This trial tests a combination of chemotherapy, an immunotherapy drug called adebrelimab, and a supportive medication to shrink bile duct or gallbladder tumors before surgery. The goal is to make the tumor easier to remove and improve outcomes.
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
Hear when a new Billiary Track Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.